Download Nuclear Medicine Therapy: Principles and Clinical by Stanley J. Goldsmith M.D. (auth.), Cumali Aktolun, Stanley PDF

By Stanley J. Goldsmith M.D. (auth.), Cumali Aktolun, Stanley J. Goldsmith (eds.)

Nuclear drugs remedy presents the cutting-edge in detailed radionuclide remedy, either in scientific perform and modern scientific research and trials. With contributions from an internationally-distinguished team of physicians and scientists, the booklet is dedicated fullyyt to using nuclear medication concepts and expertise for treatment of malignant and benign illnesses. person chapters disguise the medical ideas and scientific functions of radionuclide treatment and the kingdom of medical trials of brokers at present less than research within the treatment of tumors related to almost each organ method.

Due to overlapping curiosity in thoughts, symptoms, and medical use, the advance of radionuclide remedy draws substantial enter from different scientific experts whose collaboration is key, together with radiation and scientific oncologists, hematologists, diagnostic radiologists, hepatologists, endocrinologists, and rheumatologists. and since radionuclide treatment is a swiftly evolving box of nuclear drugs, it's the objective of this quantity to attract all experts concerned about designated radionuclide remedy and to give a contribution to the standardization of the perform globally.

Show description

Read or Download Nuclear Medicine Therapy: Principles and Clinical Applications PDF

Similar nuclear books

All About History: The World’s Worst Disasters

All approximately heritage is the stunningly realised new journal from the makers of ways it really works and All approximately house. that includes attractive illustrations, images and pictures depicting every thing from historic civilisations to the chilly struggle, All approximately historical past is obtainable and enjoyable to all and makes background enjoyable for the full relations.

Advances in Nuclear Science and Technology, Volume 23

Quantity 23 makes a speciality of perturbation Monte Carlo, non-linear kinetics, and the move of radioactive fluids in rocks.

Nuclear and Particle Physics: The Changing Interface

"Nuclear and Particle Physics" either were very specific matters for many years, and at the moment are constructing an increasing number of interfaces. hence, hitherto general equipment of particle physics are followed by way of nuclear physics. The authors try and construct bridges among either fields and provides nuclear physicists an intensive advent from the basics of particle physics to present learn during this box.

Additional resources for Nuclear Medicine Therapy: Principles and Clinical Applications

Example text

Harwood et al. 5 years involving 300 administrations of 131 I-tositumomab [32]. 8 mrem. The therapeutic radionuclide in the Zevalin® regimen is 90Y, a pure beta emitter without a gamma emission. Brehmsstrahlung radiation is produced as the beta particle looses energy as it reacts with its environment. It is readily detectable externally and consequently also presents potential radiation exposure of nearby personnel. The exposure as a consequence of Brehmsstrahlung emission is far below the allowable exposure and not hazardous to medical personnel or family members.

In 17 of these patients, a partial or complete remission was observed. In a subsequent protocol to determine a maximum tolerated dose (MTD), of 24 patients who received doses from 40 to 100 mCi/m2, 13 patients had a decrease in tumor size. Myelosuppression was observed and thrombocytopenia was the most frequent dose-limiting toxicity. Development and Assessment of Current Practice Bexxar® [131I-Tositumomab and Tositumomab] Clinical indications and efficacy: In reports dating to the early 1990s, the group at the University of Michigan developed the details of an effective protocol for the use of an anti-CD 20 murine monoclonal antibody, tositumomab, that had been prepared by Coulter, Inc (San Diego, CA) 1 Radioimmunotherapy of Lymphoma [11–14].

Major responses were observed in 25 patients (86%); CR in 23 (79%) complete responses (CRs; 79%). At a median follow-up of 42 months, the overall survival was 68% and the PFS was 42%. Fourteen of the initial group of 29 patients remain asymptomatic without interval therapy and the duration of this apparently disease-free interval was from 27 to 87 months. Two patients experienced cardiopulmonary insufficiency but responded to supportive measures. The radiation absorbed dose to their lungs was calculated to be ³27 Gy.

Download PDF sample

Rated 4.36 of 5 – based on 9 votes